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Abstract 
 
 We previously investigated the potential of targeted radiotherapy using a bismuth-213-
labeled anti-CD45 antibody to replace total body irradiation as conditioning for hematopoietic 
cell transplantation in a canine model. While this approach allowed sustained marrow 
engraftment, limited availability, high cost and short half-life of bismuth-213 induced us to 
investigate an alternative α-emitting radionuclide, astatine-211, for the same application. 
Biodistribution and toxicity studies were conducted with conjugates of the anti-murine CD45 
antibody 30F11 with either bismuth-213 or astatine-211. Mice were injected with 2-50 μCi on 10 
μg or 20 μCi on 2 or 40 μg 30F11 conjugate. Biodistribution studies showed that the spleen 
contained the highest concentration of radioactivity, ranging from 167±23 to 417±109 % injected 
dose/gram (%ID/g) after injection of the astatine-211 conjugate and 45±9 to 166±11 %ID/g after 
injection of the bismuth-213 conjugate. The higher concentrations observed for astatine-211-
labeled 30F11 were due to its longer half-life, which permitted better localization of isotope to 
the spleen before decay. Astatine-211 was more effective at producing myelosuppression for 
the same quantity of injected radioactivity. All mice injected with 20 or 50 μCi astatine-211 but 
none with the same quantities of bismuth-213 had lethal myeloablation. Severe reversible acute 
hepatic toxicity occurred with 50 μCi bismuth-213, but not with lower doses of bismuth-213 or 
with any dose of astatine-211. No renal toxicity occurred with either radionuclide. The data 
suggest that smaller quantities of astatine-211-labeled anti-CD45 antibody are sufficient to 
achieve myelosuppression and myeloablation with less non-hematological toxicity compared 
with bismuth-213-labeled antibody. 
 - 3 - 
Introduction 
 
 Allogeneic hematopoietic cell transplantation (HCT) is a curative modality for patients with 
various malignant and non-malignant hematopoietic diseases. Recently, to reduce late toxicities 
from total body γ-irradiation (TBI) while increasing specificity and efficacy, monoclonal 
antibodies (MAb) labeled with β-emitting radionuclides, such as 131 I-labeled anti-CD45 MAb, 
have been investigated (1-4). However, β-emitting radionuclides are not optimal for killing the 
targeted hematopoietic cells due to their long path length and low dose rates (5-8). Owing to the 
long β-particle path (i.e. mean range 0.4 to 5 mm (9)) the majority of the emitted energy is 
deposited outside of the targeted hematopoietic cells. Thus, while specific targeting of 
hematopoietic cells may be achieved with the MAb, the β-particles may deliver non-lethal doses 
to the targeted cells while causing non-specific toxicity to surrounding normal tissues.  
 
 In contrast to β-emissions, α-particles are characterized by very high linear energy transfer, 
with most of the particles’ energy being deposited over only a few cell diameters (i.e. 40-90 μm). 
Given this favorable feature, we investigated bismuth-213 (213Bi)-labeled anti-CD45 MAb as 
replacement for TBI in a nonmyeloablative conditioning regimen for HCT in a canine model (10-
12). Although the treatment was effective in allowing successful engraftment of marrow, several 
pragmatic obstacles precluded translating 213Bi-labeled MAbs into clinical studies including the 
very high cost of the parent radionuclide to 213Bi, actinium-225 (225Ac). Furthermore, adequate 
quantities of 225Ac were not available for clinical studies.  
 
 Astatine-211 (211At) is an alternative α-particle-emitting radionuclide for 
radioimmunotherapy (13). 211At has a longer half-life than 213Bi (7.21 h vs. 45.6 min), potentially 
making an 211At-labeled anti-CD45 MAb more effective for targeting and killing hematopoietic 
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cells. Based on our success with 213Bi-labeled anti-CD45 MAb in conditioning for HCT, we 
compared biodistributions, myelosuppression and non-hematopoietic toxicities in mice with a 
MAb targeting hematopoietic tissues after radiolabeling it with either 211At or 213Bi. The antibody, 
a rat anti-murine CD45 MAb, 30F11 (2, 14) used in the mouse provided a model for 
understanding differences between the two radionuclides. 
 
Materials and Methods 
 
 Antibody and Chemicals. The rat anti-murine CD45 MAb, 30F11, is an IgG2b MAb that 
recognizes all murine CD45 isoforms (2). The 30F11 hybridoma cell line was a gift from Dr. Irv 
Bernstein (Fred Hutchinson Cancer Research Center). The 30F11 MAb was produced by 
injecting the hybridoma into pristane-primed mice to generate ascites. The 30F11 MAb was 
purified from ascitic fluid by protein G immunoabsorption column chromatography. The protein-
reactive 213Bi-chelation reagent, isothiocyanatobenzyl-CHX-A´´-DTPA (referred to as IB-CHX-
A´´) used to modify 30F11 was purchased from Macrocyclics (Dallas, TX). The 211At-reactive 
protein modification reagent, N-(15-(aminoacyldecaborate)-4,7,10-trioxatridecanyl)-3-
maleimidopropionamide (referred to as ADTM) was prepared as previously described (15).  
 
 Radionuclides. 213Bi was obtained by elution from an 225Ac generator purchased from the 
US Department of Energy (Oak Ridge, TN) as previously described (10). 211At was obtained by 
irradiating bismuth metal with a 28 MeV α-beam in a Scandatronix MC50 cyclotron housed in 
the Department of Radiation Oncology at the University of Washington. The 211At was removed 
from irradiated bismuth targets by dry distillation and isolated in 0.05 N NaOH as previously 
described (16). 
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 Modification of MAb 30F11 for Radiolabeling. Modification of 30F11 for labeling with 
213Bi was achieved by conjugation of IB-CHX-A´´ with 30F11 in 50 mM HEPES buffer, pH 8.5, at 
room temperature for 18 h as previously described (10). Rigorous demetallation was conducted 
before conjugation with the MAb and again after the MAb-conjugate was purified. Modification of 
30F11 for labeling with 211At was achieved by treatment with 10 mM dithiotreitol (DTT) for 1 hour 
at room temperature, followed by buffer exchange into 20 mM sodium phosphate at pH 6.5, 
containing 1 mM EDTA, then addition of 10 equivalents of ADTM in DMSO to the DTT-treated 
30F11 with ADTM. After the conjugation reaction proceeded for 1 hour at room temperature, the 
reaction mixture was eluted on a PD-10 column (Sephadex G-25) pre-equilibrated in PBS, pH 
7.2. The fractions containing protein were pooled and concentrated in a Centricon-30 to provide 
the 30F11-ADTM. The 30F11-ADTM conjugates were analyzed by size-exclusion HPLC and 
IEF to assess modification to the MAb. 
 
 Radiolabeling Methods.  The 30F11-CHX-A´´ conjugate was radiolabeled with 213Bi in 0.3 
M NH4OAc, pH 4.2-4.5, for 2-5 min as described (10). The 30F11-ADTM conjugate was labeled 
with 211At as follows. To 100-200 µL of 1-5 mg/mL solution of 30F11-ADTM conjugate in PBS 
was added 2-100 μL of Na[211At]At, then 20-40 μL of chloramine-T (1 mg/mL) in H2O. The 
reaction was allowed to proceed for 30 s to 2 min; then, 20-40 μL of a 1 mg/mL solution of 
Na2S2O5 in H2O was added to quench the reaction. The reaction mixture was then passed over 
a G-25 Sephadex column (PD-10, Pharmacia) eluting with 0.9% saline (15). Fractions were 
collected and those containing protein were combined. Radiochemical yield was determined by 
the amount of radioactivity associated with the protein relative to the amount of radioactivity 
placed on the column. Radiochemical purity of the radiolabeled proteins was determined by SE-
HPLC. 
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 Animal Studies. All mouse experiments were conducted under a protocol approved by the 
Fred Hutchison Cancer Research Center Institutional Animal Care and Use Committee. Female 
BALB/c mice were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA). All 
reagents were administered to the BALB/c mice in a total volume of approximately 200 μL via 
the lateral tail vein. Sets of 30 mice were injected with either 211At- or 213Bi-labeled MAb. Of 
those mice, 20 were sacrificed at predetermined times to obtain tissue distribution data, and the 
remaining 10 were evaluated over 8 weeks for myelosuppression and toxicities. All mice were 
weighed weekly to assess for toxicity.  
 
 A total of 13 biodistribution studies were conducted. Seven experiments were conducted 
with [211At]30F11-ADTM (211At-MAb) and six with [213Bi]30F11-CHX-A´´ (213Bi-MAb). In the 
experiments, tissue distributions of conjugates containing varying quantities of both radioactivity 
and MAb were evaluated (i.e. 2 μCi/10 μg, 10 μCi/10 μg, 50 μCi/10 μg, 6 μCi/2 μg, 20 μCi/2 μg, 
20 μCi/10 μg or 20 μCi/40 μg for labeled MAbs, and an additional experiment that had 20 μCi/10 
μg for the 211At-MAb). In 213Bi (t1/2 = 45.6 min) experiments, groups of 5 mice were sacrificed at 
15, 45, 90 and 180 min after injection, when 20%, 50%, 75%, and 94% of the radionuclide had 
decayed, whereas for the 211At (t1/2 = 7.21 h) experimental groups mice were sacrificed 1, 3, 7 
and 24 h after injection, when 9%, 25%, 49% and 90% of the radionuclide had decayed. 
 
 For evaluation of tissue concentrations of radioactivity, eight tissues were examined, 
including muscle, lung, kidney, spleen, liver, intestine, neck and stomach. The spleen was used 
as a surrogate tissue for hematopoiesis as total organ weight could be serially followed in 
addition to tissue concentrations of radioactivity. Bone marrows were sent for pathological 
examination only. Blood samples were obtained by heart puncture immediately after sacrificing 
the mice. Excised tissues were blotted free of blood and weighed. The total blood volume was 
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estimated to be 6% of body weight (17). The radioactivity in each tissue was measured with a 
γ-counter (PACKARD® COBRATM GMI, Inc., Minnesota, USA), and counts per minute were 
corrected for decay of each sample from the initiation of counting. Tissue concentrations of 
radioactivity were expressed as percentages of the injected dose per gram (%ID/g). The 
calculation of %ID/g was based on standards containing 1μL of the injected dose. 
 
 For pathological examination, selected tissues (spleen, liver, kidney and bone marrow) were 
analyzed in untreated mice and those sacrificed at 24 h, 48 h, 1 week, 2 weeks and 1 month 
after injection of 10 μCi 211At on 10 μg of MAb. Necropsy was also performed to investigate the 
cause of death in the treatment groups in which lethal toxicity occurred. Each tissue was fixed in 
10% neutral buffered formaldehyde and then embedded in paraffin. Tissue sections were cut 
(4 μm) and stained with haematoxylin and eosin (HE staining) by an automatic staining system 
(Tissue-Tek® DRSTM 2000, Sakura Finetek U.S.A., Inc., CA).  
 
 Tissue Radiation Dose Estimates. Radiation absorbed doses were calculated for 213Bi and 
211At in mouse tissues using standard methods for α-particle and beta (electron) dosimetry. 
Using the mathematical formalism established by the Medical Internal Radiation Dose (MIRD) 
Committee of the Society of Nuclear Medicine (18), the absorbed doses (cGy) to target tissues 
for α-particles and electrons or β-particles were calculated from the available nuclear decay 
data (19) and biodistribution data (see Supplemental Information). The time-integrated activity 
(or total number of disintegrations) in each tissue was determined for each radionuclide by 
plotting the activity-time curve, identifying an appropriate function to represent the plotted data 
(by least-squares linear regression analysis), and by integrating the best-fit regression curve 
from time 0 to infinity. The radiation absorbed doses were then calculated using the MIRD 
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formalism. The total absorbed dose to each tissue was calculated as the sum of the alpha plus 
electron contributions.  
 
 Myelosuppression and Toxicities. Myelosuppression and non-hematological toxicities 
were evaluated in 10 surviving mice from each experimental group remaining after 
biodistribution studies. After injection of the labeled MAb, blood samples were obtained by retro-
orbital bleeding at 3 hr for 213Bi or 24 hr for 211At, and weekly (alternating between two groups of 
5 mice each) for a total of 8 weeks. Peripheral blood counts, liver enzyme, and kidney function 
were monitored in collected blood. Blood was also obtained from 5 control mice for peripheral 
blood counts or for chemistry and pooled to allow sufficient blood volume. Five percent 
ethylenediaminetetraacetic acid (EDTA) was used as anticoagulant for peripheral blood 
samples. White blood cell (WBC) counts, hemoglobin (Hb) level and platelet (Plt) counts were 
automatically measured by a quantitative automated hematology analyzer (the Sysmex XT2000i, 
Sysmex America, Mundelein, IL, USA). The analyses were conducted at the Seattle Cancer 
Care Alliance hematology laboratory. Serum aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), total bilirubin (Bil), blood urea nitrogen (BUN) and creatinine (Cr) were 
measured to evaluate liver and renal toxicities. Additionally, to determine normal ranges [mean 
± 2 standard deviations (SD)] of WBC counts, Hb level and Plt counts in peripheral blood, and 
AST, ALT, total Bil, BUN and Cr, as a baseline for comparison, blood counts and chemistry data 
were also analyzed from 42 individual untreated female BALB/c mice. Blood chemistry analyses 
were conducted by the Department of Laboratory Medicine Research Testing Services at the 
University of Washington.  
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Results 
 
 Tissue Distributions. Tissue distributions were obtained for three different quantities (2, 10 
and 40 μg) of 211At- MAb or 213Bi-MAb to determine which provided the most favorable 
biodistribution for therapy (i.e. had highest concentrations in spleen). Tissue concentrations 
were analyzed at four time points after injection to determine tissue radiation dose estimates. 
Concentrations (%ID/g) of radioactivity in selected tissues at the chosen time points after 
injection are shown in Figure 1. The spleen, which contains large numbers of CD45-containing 
hematopoietic cells, had the highest concentration of radioactivity in all experiments. Spleen 
concentrations were higher in the 211At studies than in the 213Bi studies, with the % injected 
dose/gram (mean ± standard deviation; %ID/g) ranging from167±23 (1 hr) to 417±109 (24 hr) 
after injection of the 211At conjugate and ranging from 45±9 (15 min) to 166±11 (3 h) after 
injection of the 213Bi conjugate. Interestingly, spleen weights obtained at euthanasia at each time 
point decreased dramatically from 73.9 ± 13.0 to 33.1 ± 3.2 mg at 24 h after injection of 211At 
(P<.0001, unpaired t test), but no weight changes in spleens were noted after injection of 213Bi 
(data not shown). The spleen weight changes were reversible as mice euthanized at later time 
points had normal spleens weight 2 weeks after injection of 211At. The liver contained the 
second highest concentrations, with study group averages ranging from 18-50 %ID/g for 211At 
and 19-33 %ID/g for 213Bi. The weights of the livers decreased slightly from 1.10 ± 0.09 to 0.80 ± 
0.12 g at 1 h after injection in the 211At studies, but the changes were reversible. Kidney 
concentrations were low, with group averages ranging from 8-10 %ID/g after 211At and 7-
8 %ID/g after 213Bi. Blood concentrations were similar between 213Bi and 211At groups, and 
reflected the quantity of MAb injected.  
 
 Tissue Radiation Dose Estimates. The biodistribution data were used to estimate the 
tissue radiation doses when 2, 10 or 40 μg of 211At-MAb or 213Bi-MAb were administered 
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(Table 1A). For comparison, the absorbed doses of 213Bi were multiplied by 9.49 (difference in 
half-lives) to equate the total number of 213Bi atoms to that of 211At. As a further comparison, in 
Table 1B, the tissue doses obtained using 50 μCi or, hypothetically, 500 μCi 213Bi (administered 
on the three different quantities of MAb) were compared to those obtained if 50 μCi of 211At were 
administered. The 500 μCi 213Bi value was an arbitrary value chosen as it would provide about 
the same radioactive dose as 50 μCi of 211At taking into account the 9.49x half-life factor 
between the two isotopes.  
 
 Myelosuppression. Normal ranges determined for the WBC count, Hb, and Plt count in an 
untreated cohort of mice were 4.8 ± 3.4 (x 103 mm3), 16.0 ± 2.0 (g/dl) and 92.3 ± 28.4 (x 104 
mm3), respectively. No significant cytopenias were observed in the 213Bi groups (Figure 2). On 
the other hand, lethal myelosuppression was observed in all 5 mice receiving 20 μCi 211At on 40 
μg of MAb (data not shown in the figure) or 50 μCi 211At on 10 μg MAb (minimal WBC count 
0.21 x 103 and 0.12 x 103/mm3, Plt counts 1.2 x 104 and 0.3 x 104/mm3, Hb level 1.5 and 4.2 g/dl, 
respectively). Pancytopenias started to appear 1 week after injection and were irreversible. In 
the mice receiving 20 μCi 211At on 10 μg of MAb, significant pancytopenias were observed, with 
nadirs at 2 weeks after injection (minimal WBC count 0.45 x 103/mm3). However, the 
pancytopenias resolved at 3 weeks after injection. In mice receiving 211At-MAb, leukopenia 
appeared at 24 h after injection, except in mice receiving the lowest quantity (2 μg) of MAb. In 
contrast, leukopenia was not observed in mice administered 213Bi-MAb.  
 
 Hepatic toxicity. The normal ranges [mean ± 2 SD] for AST, ALT, and total Bil were 129 ± 
96 (U/L), 52 ± 31 (U/L) and 0.48 ± 0.27 (mg/dl), respectively, in an untreated cohort of mice. 
Severe but non-lethal hepatic toxicity was observed at 3 hr after injection of 50 μCi 213Bi on 
10 μg of MAb (maximal AST 1329 U /L and ALT 928 U /L) (Figure 3A). This hepatic toxicity 
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resolved by day 15. In all 213Bi groups, except for mice given 2 μCi 213Bi on 2 μg of MAb, mild 
temporary hepatic enzyme elevations were detected at 3 h. However, the values recovered to 
near normal levels at 1 week. On the other hand, no significant hepatic toxicity was observed in 
any 211At-treated group. 
 
 Renal toxicity. The normal ranges (mean ± 2 SD) determined for BUN and Cr were 21.5 ± 
7.8 (mg/dl) and 0.35 ± 0.17 (mg/dl), respectively, in an untreated cohort of mice. No significant 
renal toxicity was observed in mice administered either 213Bi or 211At (Figure 3B).  
 
 Tissue pathology. Mice in all experimental study groups gained weight over the study 
period, except the group receiving 20 μCi 211At on 40 μg of MAb. In the group receiving 10 μCi 
211At, the bone marrow demonstrated progressive hypocellularity, and hematopoiesis 
significantly decreased at 24 h and 48 h after injection (Figure 4A). However, hematopoietic 
recovery occurred by 1 week after injection. Similarly, red pulp in the spleen significantly 
decreased and white pulp in the spleen became atrophic at 24 h and 48 h after injection 
(Figure 4B). In the 24 h sample, there was diffuse necrosis of lymphoid cells intermixed with 
proliferating lymphocytes. The white pulp became atrophic (approximately 25% of 
normal cellularity) and red pulp was depleted down to about 50% of normal cellularity at 24 h. 
Megakaryocytes remained. However, recovery of hematopoiesis in the spleen was also 
observed in the specimen 1 week after injection. There were no pathological abnormalities in 
the liver or kidney.  
 
 Necropsies were performed on mice that received 20 μCi 211At on 40 μg of MAb or 50 μCi 
211At on 10 μg of MAb to investigate the cause of spontaneous death. Based on the autopsy and 
pathological examination, it was likely that all the mice in these two groups injected with 211At 
labeled MAb died of complications of severe pancytopenia (such as anemia or sepsis). In 
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contrast to the group receiving10 μCi 211At, the bone marrow cellularity remained very sparse at 
day 10 or 12 in groups receiving 20-50 μCi 211At, documenting protracted myelosuppression 
(Figure 4C, row a). At day 11-12, the red and white pulps of the spleen were depleted down to 
25% of normal cellularity and megakaryocytes almost disappeared in the groups receiving 20 
μCi 211At. In the groups receiving 50 μCi 211At, the red and white pulps were depleted down to 5-
10% of normal cellularity and megakaryocytes were rarely observed (Figure 4C, row b). There 
was no evidence of extramedullary hematopoiesis in the liver. 
 
Discussion 
 
 The current study demonstrated that 211At was more effective than 213Bi at producing 
myelosuppression for the same quantity of injected radioactivity. All mice injected with 20 or 50 
μCi 211At but none with the same quantities of 213Bi had lethal myeloablation. Severe reversible 
acute hepatic toxicity occurred with the highest doses of 213Bi, but not with lower doses of 213Bi 
or with any dose of 211At. No renal toxicity occurred with either radionuclide. The data suggest 
that smaller μCi quantities of 211At-labeled anti-CD45 antibody are sufficient to achieve 
myelosuppression and myeloablation with less non-hematological toxicity compared with 213Bi-
labeled antibody. 
 
 Our previous study showed that the donor chimerism levels in dogs conditioned with 213Bi-
labeled anti-TCRαβ MAb (CA15.9D95) were lower than those observed in dogs conditioned with 
213Bi-labeled pan-hematopoietic anti-CD45 MAb (CA12.10C12) (10, 11, 20). The results 
suggested that 213Bi-labeled anti-CD45 MAb was more effective in killing host residual cells, 
such as natural killer (NK) cells, that are responsible for graft rejection. CD45 was an excellent 
target because it is ubiquitously expressed on both nonmalignant and malignant hematopoietic 
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cells (21-23). However, the short half-life of 213Bi presents a significant problem since it 
mandates the use of large 225Ac/213Bi generators and multiple preparations/injections per patient 
to obtain adequate doses of clinical materials for patient treatment. A further consideration is the 
fact that, at present, there is a very high cost to obtain a generator of sufficient size to conduct 
clinical studies. Therefore, a clinical study was not feasible at the current time using 213Bi. 
Additionally, the longer half-life of 211At has logistical and, potentially, therapeutic benefits.   
 
 211At is available at our institution by irradiation of a bismuth target with an α-particle beam 
from a cyclotron. An important consideration for initiating the investigation with 211At was the fact 
that recent upgrades on the cyclotron and target station used to produce 211At make it possible 
to prepare the quantities required for clinical studies, and this can be done at a much lower cost 
relative to producing 213Bi. Perhaps more importantly, the consideration for studies where 213Bi is 
replaced by 211At is the fact that the half-life of 211At (t1/2 = 7.21 h) is ~9.5x longer than that of 
213Bi (t1/2 = 45.6 min). This difference in half-life has some important benefits. One benefit is that 
there are 9.5 times the number of radioactive atoms as that of 213Bi in each mCi of 211At injected. 
Thus, for the same number of mCi of 211At as 213Bi, much higher doses can be obtained, or 
considerably lower quantities of 211At might be used to deliver a therapeutic dose. Another 
benefit of the longer half-life is the fact that a smaller percentage of the injected radioactivity will 
decay during the period of targeting hematopoietic cells, potentially resulting in more specific 
delivery of the radiation. 
 
 In the current study, labeling MAb 30F11 with the two radionuclides required use of different 
chemical modifications that could potentially affect the tissue distribution. Further, biodistribution 
of the radiolabeled MAb conjugates (30F11-CHX-A´´ and 30F11-ADTM) were only relevant over 
the period where most of the radioactivity decays, potentially making the relative biodistributions 
very different given the different half-lives of the two isotopes. To label 213Bi, MAb 30F11 was 
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conjugated with a benzylisothiocyanate-cyclohexyl derivative of 
diethylenetetraaminepentaacetic acid (IB-CHX-A´´) which had been used in our previous canine 
conditioning studies. MAb conjugates of IB-CHX-A´´ were rapidly labeled (5 min) in high yield 
(>80%) and provided good in vivo stability during the period of 213Bi decay. Stability of the label 
had been a problem for antibodies labeled with 211At (24). Although 211At-labeled benzoate 
esters could be used for stable labeling some MAbs, an investigation of 30F11 labeled with N-
hydroxysuccinimidyl 3-[211At]astatobenzoate (25) indicated that it was not stable in vivo 
(unpublished). Therefore, an alternate 211At-labeling conjugate, a recently developed reagent 
(15, 26), N-(15-(aminoacyldecaborate)-4,7.10-trioxatridecanyl)-3-maleimide (ADTM), was used. 
The use of MAb-ADTM conjugates provided high radiochemical yields (70-80%) through direct 
labeling of 211At, and provided high in vivo stability to deastatination.  
 
 The biodistribution studies showed that the much higher radiation doses delivered by 211At 
depleted the hematopoietic cells and accounted for the differences seen in the spleen weights. 
While a large portion of the difference in radiation doses was provided by the fact that there are 
9.49 times more 211At atoms per μCi administered, it appears that another factor of 2x in the 
dose may be due to the longer half-life of 211At, permitting more localization of MAb to the 
spleen prior to decay. Thus, from the tissue radiation dose estimates, 500 μCi of 213Bi would 
deliver less than half the dose to the target (spleen) of 50 μCi 211At if the radionuclides were on 
10 μg of MAb. As might be expected from the biodistribution and tissue dose estimates, the 
blood count data indicated that myelosuppression was more effective with the 211At-MAb for the 
same μCi amount of 213Bi-MAb. 
 
 In this study, severe hepatic toxicity appeared in the mice receiving the highest dose 
(50 μCi) of 213Bi-MAb, presumably due to the abundance of hematopoietic cells and Kupffer 
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cells in the liver expressing the CD45 antigen. There may also be a non-specific dose 
contribution as immunoglobulins from the blood stream are known to be trapped in the liver, 
resulting in the radiolabeled MAb being trapped even though CD45 is not expressed on 
hepatocytes (7). In the previous canine study, the dog receiving the highest dose of 8.8 mCi/kg 
213Bi labeled anti-CD45 MAb also showed marked elevation of hepatic enzymes and evidence of 
liver failure with the development of ascites due to toxicity from the radioimmunotherapy (10). 
Based on the present and previous data, hepatic toxicity of 213Bi-labeled anti-CD45 MAb can be 
considered dose-limiting. The observed hepatic toxicity in the 213Bi studies was likely caused by 
deposition of 213Bi-labeled MAb in the liver. The nature of conjugate molecule (i.e. CHX-A´´ or 
ADTM) to label the MAb with radionuclide might also contribute to hepatic deposition, but there 
are no data suggesting that either conjugate specifically localizes to liver.  
 
 The overall objective of our continuing research effort is to determine if MAbs labeled with 
an α-particle emitting radionuclide can deliver a marrow-ablative dose without the other organ 
toxicities associated with high-dose conditioning regimens. Our earlier studies demonstrated 
that 213Bi-labeled anti-CD45 MAb provided adequate myelosuppression to obtain stable 
chimeras in the dog model. From previous dog data it was estimated that 1.5-2 mCi 213Bi/kg on 
0.5 mg anti-CD45 MAb/kg would likely be required in patients to obtain stable engraftment. This 
study demonstrated that 211At was more effective at myelosuppression for the same quantity of 
radioactivity injected than 213Bi without significant non-hematopoietic toxicity. Based on the fact 
that there are fewer barriers to clinical studies with 211At, and the encouraging results obtained 
in this investigation, further studies in the dog model with 211At-labeled anti-CD45 MAb are 
underway.  
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Table 1.  Calculated tissue dose estimates for [213Bi]30F11 and [211At]30F11. 
 
A.  Radiation absorbed doses per unit administered activity (cGy / μCi) 
 Nuclide Bi-213 Bi x 9.49* At-211   Bi-213 Bi x 9.49* At-211   Bi-213,  Bi x 9.49* At-211 
MAb wt 2 μg   2 μg   10 μg   10 μg   40 μg   40 μg 
              
Blood 0.78 7.38 9.00  1.28 12.15 8.01  3.42 32.46 12.60 
Muscle 0.19 1.84 1.11  0.19 1.84 1.96  0.31 2.95 1.98 
Lung 2.68 25.43 13.30  2.35 22.30 14.67  2.82 26.76 12.30 
Kidney 1.13 10.72 15.70  1.42 13.48 17.30  2.24 21.26 12.10 
Spleen 17.80 168.92 327.00  23.30 221.12 589.00  21.40 203.09 419.00 
Liver 4.12 39.10 52.10  5.13 48.68 47.80  3.71 35.21 27.00 
Intestine 0.16 1.47 7.02  0.27 2.58 7.32  0.74 7.01 9.13 
Neck 0.37 3.50 11.10  0.43 4.06 8.82  0.72 6.82 10.60 
Stomach 0.19 1.84 3.35   0.21 2.03 7.77   0.62 5.90 4.49 
 
B.  Organ or tissue absorbed dose (cGy) through complete decay of the activities administered. 
 Nuclide Bi-213 Bi-213 At-213,   Bi-213 Bi-213 At-211   Bi-213 Bi-213 At-211 
 MAb wt 2 μg 2 μg 2 μg   10 μg 10 μg 10 μg   40 μg 40 μg 40 μg 
 Activity 50 μCi 500 μCi** 50 μCi   50 μCi 500 μCi** 50 μCi   50 μCi 500 μCi** 50 μCi 
              
Blood 39 389 450  64 640 401  171 1710 630 
Muscle 10 97 56  10 97 98  16 156 99 
Lung 134 1340 665  118 1175 734  141 1410 615 
Kidney 57 565 785  71 710 865  112 1120 605 
Spleen 890 8900 16350  1165 11650 29450  1070 10700 20950 
Liver 206 2060 2605  257 2565 2390  186 1855 1350 
Intestine 8 78 351  14 136 366  37 370 457 
Neck 18 185 555  21 214 441  36 360 530 
Stomach 10 97 168   11 107 389   31 311 225 
*This value represents an equivalent number of 213Bi atoms to 211At atoms obtained by multiplying by a half-life difference factor 
(9.49x) 
**The 500 μCi is an arbitrary value chosen to provide about the same dose to most tissues; 10x is similar to 9.49x half-life factor. 
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Figure Legends 
 
Figure 1. 213Bi- and 211At-labeled rat anti-mouse anti-CD45 antibody 30F11 conjugate 
(213Bi- and 211At-MAb) biodistributions 
Tissue biodistributions were obtained in mice to assess MAb targeting to spleen, which has high 
concentrations of CD45-containing cells, and to determine the effect of varying the quantity of 
MAb on tissue concentrations. The graphs of the tissue concentrations, expressed as percent 
injected dose / gram (%ID/g), for studies that employed 2 μg (red bars), 10 μg (blue bars) or 40 
μg (green) of MAb are shown. Data were obtained at 15, 45, 90 and 180 min after injection of 
213Bi-MAb and at 1, 3, 7 and 24 h after injection of 211At-MAb. Data were obtained from groups 
of 5 mice per time point and were plotted as average values ± one standard deviation. Values 
plotted for injections of 2 and 40 μg quantities of MAb were obtained from single experiments (5 
mice per time point), whereas values plotted for 10 μg were averaged from 3 (213Bi) or 4 (211At) 
separate experiments (total of 15-20 mice per time point) because the biodistributions of MAb 
labeled with a specific radionuclide differed only when the quantities of MAb were different. Note 
that the y-axis maximum is 200 %ID/g for 213Bi-MAb and 500 %ID/g for 211At-MAb.  
 
Figure 2. Myelosupression with varying amounts (2, 10, 20, 50 μCi) of 213Bi-MAb or 211At-
MAb. Peripheral blood counts were monitored in collected blood at 180 min and then weekly for 
213Bi and at 24 h and then weekly for 211At. White blood cell (WBC) counts, hemoglobin (Hb) 
levels and platelet (Plt) counts were monitored up to 8 weeks after injection. The displayed data 
were obtained from mice treated with 2, 10, 20 and 50 μCi of 213Bi or 211At on 10 μg of MAb. The 
dashed lines indicate normal ranges (mean ± 2 standard deviations) which were calculated with 
data obtained from 42 untreated female BALB/c mice. 
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Figure 3. Hepatic and renal toxicity with varying amounts (2, 10, 20, 50 μCi) of 213Bi-MAb 
211At-MAb. Hepatic and renal toxicities were monitored in sera from peripheral blood collected 
at 180 min (213Bi) or 24h (211At) after injection, and then weekly. Liver toxicity was assessed by 
monitoring the enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT), 
and total bilirubin (T-Bil). Renal toxicity was assessed by monitoring the blood urea nitrogen 
(BUN) and creatinine (Cre). The monitoring was performed up to 8 weeks after injection. The 
displayed data were obtained from mice treated with 2, 10, 20 and 50 μCi of 213Bi or 211At on 10 
μg of MAb. The dashed lines indicate normal ranges (mean ± 2 standard deviations) which were 
calculated with data obtained from 42 untreated female BALB/c mice.  
 
Figure 4. Pathological changes in the spleen and bone marrow after injection of 211At-
MAb. Pathological examination of bone marrow from femurs (Panel A) and the spleens (Panel 
B) was performed on mice sacrificed 24, 48 h, 1, 2, 4 weeks after injection of 10 μCi/10 μg 211At-
MAb. Pathological examination of the bone marrow from femur or sternum was conducted on 
necropsy samples on day 12 and day 10 after 20 μCi/40 μg or 50 μCi/10 μg 211At-MAb were 
administered, respectively (Panel C; row a) and the spleens on day 12 and day 11 after 20 
μCi/40 μg or 50 μCi/10 μg 211At-MAb were administered, respectively (Panel C; row b). 
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